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journal homepage: www.jfma-onl ine.comLETTER TO THE EDITORAlanine transaminase as a single marker is
not reliable for selecting candidates of
pegylated interferon and ribavirin treatmentTo the Editor,
We read with great interest the article by Lin et al.1 They
studied the efficacy and safety of pegylated interferon a-2a
and ribavirin in 12 hemophilic patients with chronic hepa-
titis C. The current study is appreciable since hemophilic
patients are considered as a special patients group and the
data regarding the treatment of hepatitis C in these in-
dividuals are limited in the literature.
However, we have some concerns about the study
design and results. They excluded 23 patients from the
study because they had normal alanine transaminase (ALT)
level. Since the study population was not assessed for liver
fibrosis, it seems that patient exclusion by ALT level could
be misleading. We would like to mention that about 30% of
hepatitis C virus (HCV) infected patients have persistently
normal ALT levels and the majority of them have some
degree of liver fibrosis; however, the liver damage can be
significant in some instances.2,3 Although liver biopsy is still
the goal standard method for determination of liver dam-
age, fibrosis severity in hemophilic patients should be
evaluated by noninvasive methods instead of liver biopsy
because bleeding tendency among these patients may be
life threatening. Transient elastography (Fibroscan) as a
liver stiffness measurement can be performed in this sit-
uation.4,5 It seems that treatment delay in patients with
chronic HCV infection and normal ALT level probably leads
to liver disease progression over time. Additionally, in
Figure 1, it was stated that among eight patients who were
infected with HCV genotype 1/4, five (42%) patients
completed the treatment course and three patients dis-
continued the treatment, whereas the correct percent for
the patients completed the treatment course should be
62.5% instead of 42%, which was mentioned in Figure 1.Conflicts of interest: The authors have no conflicts of interest
relevant to this article.
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0929-6646/Copyright ª 2014, Elsevier Taiwan LLC & Formosan MedicaAlso, HCV RNA level was assessed among the study popu-
lation, while the authors did not point to the result of this
parameter as an important factor in response to treat-
ment. A former study reported the significant impact of
HCV RNA level on sustained virological response (SVR) in
hemophilic patients with HCV infection who were treated
with pegylated interferon and ribavirin.6
Finally, we believe that ALT level as a single marker
in patients with chronic HCV infection cannot participate
in making clinical decisions. We agree with the authors
that there is a need to design a large-scale multicenter
study among hemophilic patients with HCV infection in this
area.
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